Compare · NVO vs PRAX
NVO vs PRAX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Praxis Precision Medicines Inc. (PRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 25.9x PRAX ($7.06B).
- PRAX has been more active in the news (9 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 17 for PRAX).
- Company
- Novo Nordisk A/S
- Praxis Precision Medicines Inc.
- Price
- -
- -
- Market cap
- $183.15B
- $7.06B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 9
- Recent ratings
- 25
- 17
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Praxis Precision Medicines Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest PRAX
- Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
- Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Praxis Precision Medicines Inc. filed SEC Form 8-K: Other Events
- Praxis Precision Medicines Provides Vormatrigine Program Update
- Principal Accounting Officer Mastrocola Lauren was granted 127 shares, increasing direct ownership by 0.94% to 13,573 units (SEC Form 4)
- General Counsel and Secretary Nemiroff Alex was granted 78 shares, increasing direct ownership by 0.30% to 26,011 units (SEC Form 4)
- Chief Financial Officer Kelly Timothy Edwin was granted 121 shares, increasing direct ownership by 0.39% to 31,167 units (SEC Form 4)
- Chief Operating Officer Sniecinski Megan was granted 89 shares, increasing direct ownership by 0.31% to 28,664 units (SEC Form 4)
- Chief Executive Officer Souza Marcio was granted 126 shares, increasing direct ownership by 0.16% to 77,016 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Praxis Precision Medicines Inc.